Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin

Journal of Thoracic Oncology

Volumn 3, Issue 2, 2008, Pages 117-124

  Reckamp, Karen L ^a   Gardner, Brian K ^b   Figlin, Robert A ^a   Elashoff, David ^b   Krysan, Kostyantyn ^b   Dohadwala, Mariam ^b   Mao, Jenny ^b   Sharma, Sherven ^b   Inge, Landon ^b   Rajasekaran, Ayyappan ^b   Dubinett, Steven M ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarkers; Cyclooxygenase 2; Epidermal growth factor receptor; Non small cell lung cancer

Indexed keywords

CELECOXIB; CHEMOKINE; CHEMOKINE CCL15; CYCLOOXYGENASE 2; ERLOTINIB; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; UVOMORULIN;

ANGIOGENESIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL TRANSFORMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; HUMAN; LUNG NON SMALL CELL CANCER; MESENCHYME CELL; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

EID: 40049090209     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181622bef     Document Type: Article

References (59)

1. A Jemal R Siegel E Ward Cancer statistics, 2007 CA Cancer J Clin 57 2007 43 66
2. FA Shepherd J Rodrigues Pereira T Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
3. TJ Lynch AA Adjei PA Bunn Jr Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents Clin Cancer Res 12 2006 4365s 4371s
4. J Baselga CL Arteaga Critical update and emerging trends in epidermal growth factor receptor targeting in cancer J Clin Oncol 23 2005 2445 2459
5. R Tibes J Trent R Kurzrock Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics Annu Rev Pharmacol Toxicol 45 2005 357 384
6. K Krysan KL Reckamp H Dalwadi Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner Cancer Res 65 2005 6275 6281
7. FG Buchanan D Wang F Bargiacchi RN DuBois Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor J Biol Chem 278 2003 35451 35457
8. R Pai B Soreghan IL Szabo Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy Nat Med 8 2002 289 293
9. RJ Coffey CJ Hawkey L Damstrup Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells Proc Natl Acad Sci USA 94 1997 657 662
10. M Dohadwala SC Yang J Luo Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer Cancer Res 66 2006 5338 5345
11. S Thomson E Buck F Petti Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition Cancer Res 65 2005 9455 9462
12. S Kase K Sugio K Yamazaki Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance Clin Cancer Res 6 2000 4789 4796
13. M Polette P Birembaut Membrane-type metalloproteinases in tumor invasion Int J Biochem Cell Biol 30 1998 1195 1202
14. IS Aljada N Ramnath K Donohue Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer J Clin Oncol 22 2004 3218 3229
15. M Takeichi Cadherin cell adhesion receptors as a morphogenetic regulator Science 251 1991 1451 1455
16. RM Bremnes R Veve E Gabrielson High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer J Clin Oncol 20 2002 2417 2428
17. V Noe B Fingleton K Jacobs Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1 J Cell Sci 114 2001 111 118
18. AO Chan KM Chu SK Lam Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin Cancer 104 2005 740 746
19. AO Chan KM Chu SK Lam Soluble E-cadherin is an independent pretherapeutic factor for long-term survival in gastric cancer J Clin Oncol 21 2003 2288 2293
20. KN Syrigos KJ Harrington AJ Karayiannakis Circulating soluble E-cadherin levels are of prognostic significance in patients with multiple myeloma Anticancer Res 24 2004 2027 2031
21. C Wilmanns J Grossmann S Steinhauer Soluble serum E-cadherin as a marker of tumour progression in colorectal cancer patients Clin Exp Metastasis 21 2004 75 78
22. K Charalabopoulos A Gogali Y Dalavaga The clinical significance of soluble E-cadherin in nonsmall cell lung cancer Exp Oncol 28 2006 83 85
23. M Katayama S Hirai K Kamihagi Soluble E-cadherin fragments increased in circulation of cancer patients Br J Cancer 69 1994 580 585
24. RE Banks WH Porter P Whelan PH Smith PJ Selby Soluble forms of the adhesion molecule E-cadherin in urine J Clin Pathol 48 1995 179 180
25. B Nawrocki-Raby C Gilles M Polette Upregulation of MMPs by soluble E-cadherin in human lung tumor cells Int J Cancer 105 2003 790 795
26. M Egeblad Z Werb New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2 2002 161 174
27. AR Nelson B Fingleton ML Rothenberg LM Matrisian Matrix metalloproteinases: biologic activity and clinical implications J Clin Oncol 18 2000 1135 1149
28. LM Coussens B Fingleton LM Matrisian Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 295 2002 2387 2392
29. M Dohadwala RK Batra J Luo Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion J Biol Chem 277 2002 50828 50833
30. Y Jiang ID Goldberg YE Shi Complex roles of tissue inhibitors of metalloproteinases in cancer Oncogene 21 2002 2245 2252
31. V Gouyer M Conti P Devos Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent Cancer 103 2005 1676 1684
32. S Ylisirnio M Hoyhtya R Makitaro Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer Clin Cancer Res 7 2001 1633 1637
33. SM Dubinett D Elashoff M Meyerson Assessing prognosis in non-small-cell lung cancer: avenues to a more complete picture? J Clin Oncol 22 2004 3209 3211
34. T Leinonen R Pirinen J Bohm Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis Lung Cancer 51 2006 313 321
35. P Iniesta A Moran C De Juan Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer Oncol Rep 17 2007 217 223
36. K Ondo K Sugio K Yamazaki The significance of serum active matrix metalloproteinase-9 in patients with non-small cell lung cancer Lung Cancer 46 2004 205 213
37. J Rollin S Regina P Vourc'h Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer Lung Cancer 56 2007 273 280
38. S Ishikawa K Takenaka K Yanagihara Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer Clin Cancer Res 10 2004 6579 6585
39. BJ Rollins Chemokines Blood 90 1997 909 928
40. M Baggiolini B Dewald B Moser Human chemokines: an update Annu Rev Immunol 15 1997 675 705
41. AD Luster Chemokines–chemotactic cytokines that mediate inflammation N Engl J Med 338 1998 436 445
42. F Balkwill Cancer and the chemokine network Nat Rev Cancer 4 2004 540 550
43. H Spring T Schuler B Arnold GJ Hammerling R Ganss Chemokines direct endothelial progenitors into tumor neovessels Proc Natl Acad Sci USA 102 2005 18111 18116
44. LM Coussens Z Werb Inflammation and cancer Nature 420 2002 860 867
45. J Hwang CW Kim KN Son Angiogenic activity of human CC chemokine CCL15 in vitro and in vivo FEBS Lett 570 2004 47 51
46. J Ko IS Kim SW Jang Leukotactin-1/CCL15-induced chemotaxis signaling through CCR1 in HOS cells FEBS Lett 515 2002 159 164
47. R Richter R Bistrian S Escher Quantum proteolytic activation of chemokine CCL15 by neutrophil granulocytes modulates mononuclear cell adhesiveness J Immunol 175 2005 1599 1608
48. X Wu J Fan X Wang Downregulation of CCR1 inhibits human hepatocellular carcinoma cell invasion Biochem Biophys Res Commun 355 2007 866 871
49. H Harlin TV Kuna AC Peterson Y Meng TF Gajewski Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites Cancer Immunol Immunother 55 2006 1185 1197
50. KL Reckamp K Krysan JD Morrow A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer Clin Cancer Res 12 2006 3381 3388
51. FE Baratelli N Heuze-Vourc'h K Krysan Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix J Immunol 173 2004 5458 5466
52. GE Kim YB Kim NH Cho Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival Clin Cancer Res 10 2004 1366 1374
53. CJ Torrance PE Jackson E Montgomery Combinatorial chemoprevention of intestinal neoplasia Nat Med 6 2000 1024 1028
54. Z Chen X Zhang M Li Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck Clin Cancer Res 10 2004 5930 5939
55. SM Gadgeel JC Ruckdeschel EI Heath Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC) J Thorac Oncol 2 2007 299 305
56. KJ O'Byrne S Danson D Dunlop Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer J Clin Oncol 25 2007 3266 3273
57. SE Witta RM Gemmill FR Hirsch Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines Cancer Res 66 2006 944 950
58. M Pold LX Zhu S Sharma Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer Cancer Res 64 2004 1853 1860
59. Y Zhou J Ran C Tang Effect of celecoxib on E-cadherin, VEGF, microvessel density and apoptosis in gastric cancer Cancer Biol Ther 6 2007 269 275